# Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma

> **NCT05117814** · NA · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 20 (estimated)

## Conditions studied

- CNS Lymphoma

## Interventions

- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT05117814
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09
- **Primary completion:** 2023-01
- **Final completion:** 2025-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05117814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05117814, "Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05117814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*